Fundraising FoxInvivo Capital Partners
Venture capitalBarcelona · Pre-Seed–Series A · 13 people tracked
Find your way into Invivo Capital Partners
Each arrow is one introduction. Sign up to fill in the first one.
Ask Esther Riambau to introduce you to Gemma Guinart
You →Esther · together at UPF Ventures →Gemma
Ask Jamie Chen to introduce you to Borja Ruiz
You →Jamie · together at Hospital Sant Joan de Déu - Barcelona →Borja
Ask Sam Okafor to introduce you to Cinta Diez
You →Sam · together at EIT Health Accelerator →Cinta
- Laura Rodríguez171 people can intro you
- Albert Ferrer64 people can intro you
- Luis Pareras24 people can intro you
Sign up to find every way you can get introduced to Invivo Capital Partners
- Your email: who you already know at Invivo Capital Partners, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Invivo Capital Partners team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
Invivo Partners backs early-stage science-driven companies, concentrating on biotechnology firms developing innovative drugs, especially advanced therapies and synthetic biology, as well as ventures spanning AI and deeptech. It invests at pre-seed (company creation), seed (preclinical stage), and directly at Series A for companies 1-2 years from First-in-Human trials. The firm targets European businesses with a special focus on Spanish opportunities, deploying initial checks of 2-4M€ and follow-ons up to 10M€ per company after milestones. Backed by institutional investors including the European Investment Fund, ICO, ICF, IVF, and Barcelona City Council, the team combines scientific, technical, and financial expertise to build a leading position in Europe's biotech industry.
Source: firm website, verified Aug 7, 2026.
Team · 13 people
from the firm's website & public directories
What they invest in
from 19 of 33 portfolio companiesBiotech ×15Healthtech ×10Medical Devices ×8Longevity ×4Deep Tech ×3Digital Health ×3AI & Machine Learning ×2Fintech ×2
HQs:Spain×6European Union×1Netherlands×1United States×1
Investments · 33 tracked
founders shown can be your intro path
Alnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.
BiotechDigital HealthMedical DevicesCambridge, US
John Maraganore(Founder)inPhillip Sharp(Founder)David Bartel(Founder)Thomas Tuschl(Founder)Paul Schimmel(Founder)Phillip Zamore(Founder)
Co-investorsARCH Venture PartnersAtlas VentureBlackstone Life SciencesCardinal PartnersAlexandria
BioCryst is a global biotechnology company focused on drug discovery, development, and commercialization of oral small-molecule and injectable protein therapeutics.
Biotech
Babar Ghias(Chief Financial Officer and Treasurer)Alane P. Barnes(Chief Legal Officer and Corporate Secretary)inRonald S. Dullinger(Chief Commercial Officer)Sandeep M. Menon(Chief Research and Development Officer)Charles K. Gayer(President and Chief Executive Officer)in
Arthex Biotech develops antisense RNA compounds to treat diseases with unmet medical needs.
AI & Machine LearningBiotechMedical Devices
Beatriz Llamusí(Chief Scientific Officer & Co-Founder)in
Co-investorsHadean VenturesSound BioventuresBpifranceColumbus Venture PartnersAdBio partners
The European Investment Fund is a multilateral development bank with AAA credit ratings that provides capital and financing to foster economic impact through its strong balance sheet and governance.
CleantechClimate TechEnergyEnterprise SoftwareFintechImpact & Social GoodLuxembourg, EU
Co-investorsEIFAlpine Space VenturesBOMCrowberry CapitalKhanuM80 Partners+3 more
Official municipal website of the city of Barcelona, providing residents with access to public services, administrative procedures, cultural agenda, and city information.
GovTechBarcelona, ES
Co-investorsLumo LabsStep VentureTarget Global
Corteria Pharma develops interceptive therapies aimed at treating subpopulations of patients with heart failure, sarcopenia, and obesity.
BiotechDigital HealthHealthtechLongevity
Philip JaniakinMarie-Laure OzouxinRégis OlivierinFrancesca C. LawsonMark KowalaEleonore Jouannyin
Co-investorsFountain Healthcare PartnersJeito CapitalKurma PartnersOrbiMedV-Bio VenturesOmnes Capital+1 more
Freeline develops gene therapies aimed at stopping the progression of chronic diseases with single-dose genetic medicines.
BiotechHealthtechLongevity
Co-investorsAlbionVCWellington ManagementUCL Technology Fund
The Instituto de Crédito Oficial (ICO) is Spain's state-owned finance institution that provides loans, guarantee lines, and direct digital financing to Spanish SMEs, freelancers, and companies for domestic activity, investment, exports, and internationalization.
FintechGovTechImpact & Social Good
Minoryx is a registration-stage biotech company developing novel therapies for severe, orphan genetic diseases of the central nervous system, with a lead compound (leriglitazone) in clinical trials for conditions including cerebral adrenoleukodystrophy, Friedreich's Ataxia, and Rett syndrome.
BiotechDeep TechHealthtechMedical DevicesMataró, ES
Marc Martinell(Co-Founder & Chief Executive Officer)in
Co-investorsChiesi VenturesCriteria Bio VenturesFund+Kurma PartnersRoche Venture FundYsios Capital+5 more
Neumirna develops miRNA-based therapies for neurological diseases such as epilepsy and Parkinson's.
BiotechLongevity
Co-investorsIaso VenturesSunstone Capital
OneChain Immunotherapeutics is a clinical-stage biotech developing CAR-T cell therapy candidates as treatments for oncological diseases.
BiotechHealthtech
Pablo Menéndez(Scientific Founder)
Peptomyc is a biotech company developing MYC inhibitors for cancer treatment, based on the Omomyc molecule, and is advancing them through preclinical and clinical trials.
BiotechDeep TechHealthtechMedical DevicesBarcelona, ES
Dr. Marie-Eve Beaulieu(Co-founder)Laura Soucek(Co-founder & CSO (former CEO))in
Co-investorsAsabys PartnersAurora ScienceAlta Life Sciences
ProQR develops medicines for patients with unmet medical needs, focusing on therapeutic development in biotech.
BiotechHealthtechMedical DevicesLeiden, NL
Co-investorsPontifax Venture CapitalSofinnova PartnersAescap Life Sciences
CSL is a biotechnology company that develops and manufactures plasma-derived and other therapies, including biotherapies for rare and serious diseases, vaccines, and treatments for iron deficiency and kidney disease.
BiotechHealthtechMedical Devices
Joan Perello Bestard(Founder)inCris Calsadain
Co-investorsAndera PartnersColumbus Venture PartnersCriteria Bio VenturesYsios Capital
Telomere Therapeutics is a gene therapy company developing treatments that repair telomeres to address organ fibrosis and telomere-dysfunction syndromes.
BiotechHealthtechLongevity
Telum Therapeutics develops antimicrobial drugs using synthetic biology and AI-driven machine learning, specializing in engineered lytic proteins to address multidrug-resistant infections.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesNoáin, ES
Subhendu Basu(Chief Executive Officer)inRoberto Díez(Chief Operating Officer)inDiana Gutiérrez(Chief Scientific Officer)in
Co-investorsAMR Action Fund
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
EsobiotecGvaIcfIntegra TherapeuticsNeumirnaOneChain ImmunotherapeuticsPulmobioPulmobioticsSenti BioSignadori BioSignadoribioTelomere TherapeuticsTelum TherapeuticsVersantis
Exits · 2
2 IPOsAlnylam PharmaceuticalsNASDAQ: ALNYBioCryst PharmaceuticalsNASDAQ: BCRX
Frequently asked questions
- How many investments has Invivo Capital Partners made?
- Invivo Capital Partners has 33 tracked investments, 2 of which have exited.
- What stage does Invivo Capital Partners invest at?
- Invivo Capital Partners invests at the Pre-Seed, Seed, Series A stages.
- What is Invivo Capital Partners's typical check size?
- Invivo Capital Partners typically writes checks of $2.2M – $4.3M.
- What sectors does Invivo Capital Partners focus on?
- Invivo Capital Partners focuses on AI & Machine Learning, Biotech, Deep Tech, Healthtech, Medical Devices.
- Where is Invivo Capital Partners located?
- Invivo Capital Partners is headquartered in Barcelona, ES.
- Who does Invivo Capital Partners co-invest with?
- Invivo Capital Partners most often shares deals with AdBio partners, Criteria Bio Ventures, Kurma Partners, among 35 tracked co-investors.
Images
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Future Positive Capital is a venture firm backing entrepreneurs building companies that address large-scale global challenges across health, sustainability and technology.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.